Literature DB >> 17296640

N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension.

Hanno H Leuchte1, Michal El Nounou, Juergen Christian Tuerpe, Bertram Hartmann, Rainer A Baumgartner, Michael Vogeser, Olaf Muehling, Jürgen Behr.   

Abstract

BACKGROUND: N-terminal pro-brain natriuretic peptide (NT-proBNP) is a byproduct of the brain natriuretic peptide (BNP) that was shown to be of prognostic value in pulmonary hypertension (PH). The role of NT-proBNP in PH has to be determined, especially under the influence of renal impairment that might lead to an accumulation of the peptide, and may be a sign of increased mortality per se.
METHODS: We assessed NT-proBNP, BNP, renal function, and hemodynamic parameters (during right-heart catheterization) in 118 consecutive patients with isolated PH, excluding left-heart disease. Depending on the calculated creatinine clearance, patients were classified into different groups of renal function. Correlation analysis was performed on all key parameters. Results were then compared between the levels of renal function. The prognostic value of each parameter was assessed during a mean follow-up period of 10 months.
RESULTS: Twenty-two patients (approximately 19%) had significantly impaired renal function (creatinine clearance < 60 mL/min). Although the overall levels of NT-proBNP were correlated with hemodynamics, we observed no correlation in the group with significant renal dysfunction. Moreover, NT-proBNP was related to creatinine clearance. Finally, NT-proBNP and renal insufficiency were independent predictors of death during univariate and multivariate analysis, whereas BNP only predicted mortality in univariate analysis.
CONCLUSIONS: The diagnostic accuracy of NT-proBNP as a parameter of the hemodynamic status is diminished by renal function. However, NT-proBNP could be superior to BNP as a survival parameter in PH because it integrates hemodynamic impairment and renal insufficiency, which serves as a sign of increased mortality per se.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17296640     DOI: 10.1378/chest.06-1758

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  40 in total

1.  Sildenafil improves renal function in patients with pulmonary arterial hypertension.

Authors:  David J Webb; Jean-Luc Vachiery; Lie-Ju Hwang; Julie O Maurey
Journal:  Br J Clin Pharmacol       Date:  2015-05-19       Impact factor: 4.335

Review 2.  Biomarkers and prognostic indicators in pulmonary arterial hypertension.

Authors:  Carlos Jardim; Rogerio Souza
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

3.  CT-proET1 predicts pulmonary hemodynamics in Scleroderma-associated pulmonary hypertension.

Authors:  Henrik Ten Freyhaus; Daniel Dumitrescu; Sonja Schnorbach; Kai Kappert; Thomas Viethen; Martin Hellmich; Nicolas Hunzelmann; Stephan Rosenkranz
Journal:  Clin Res Cardiol       Date:  2015-02-24       Impact factor: 5.460

4.  Strain and strain rate echocardiography for evaluation of right ventricular dysfunction in patients with idiopathic pulmonary arterial hypertension.

Authors:  Arthur Filusch; Derliz Mereles; Ekkehard Gruenig; Sebastian Buss; Hugo A Katus; F Joachim Meyer
Journal:  Clin Res Cardiol       Date:  2010-03-30       Impact factor: 5.460

5.  The N-terminal pro-brain-type natriuretic peptide based short-term prognosis in patients with acute pulmonary embolism according to renal function.

Authors:  T M Berghaus; W Behr; W von Scheidt; M Schwaiblmair
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

Review 6.  The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension.

Authors:  Manreet Kanwar; Amresh Raina; Lisa Lohmueller; Jidapa Kraisangka; Raymond Benza
Journal:  Curr Hypertens Rep       Date:  2019-04-25       Impact factor: 5.369

7.  Cardio-pulmonary MRI for detection of treatment response after a single BPA treatment session in CTEPH patients.

Authors:  Christian Schoenfeld; Jan B Hinrichs; Karen M Olsson; Martin-Alexander Kuettner; Julius Renne; Till Kaireit; Christoph Czerner; Frank Wacker; Marius M Hoeper; Bernhard C Meyer; Jens Vogel-Claussen
Journal:  Eur Radiol       Date:  2018-10-11       Impact factor: 5.315

8.  Assessment of N-terminal prohormone B-type natriuretic peptide as a measure of vascular and ventricular function in pediatric pulmonary arterial hypertension.

Authors:  Vitaly O Kheyfets; Jamie Dunning; Uyen Truong; D Dunbar Ivy; Kendall A Hunter; Robin Shandas
Journal:  Pulm Circ       Date:  2015-12       Impact factor: 3.017

9.  Clinical and haemodynamic evaluation of chronic thromboembolic pulmonary hypertension patients scheduled for pulmonary thromboendarterectomy: Is schistosomiasis hypertension an important confounding factor?

Authors:  Mario Terra-Filho; Marcos Figueiredo Mello; Mônica Silveira Lapa; Ricardo Henrique Oliveira Braga Teixeira; Fábio Biscegli Jatene
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

10.  Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.